Pleco Therapeutics is a Dutch private limited company, established to develop a portfolio of therapies in the field of cancer medicine. Pleco utilises a global network of academic centres and contract research organisations to test highly-efficient Fixed-Dose Combinations, repurposing existing therapies. The first products are currently being tested in the clinic. Pleco targets diseases with orphan designation to expedite the development process. The current programs focus on treatments for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, and Small-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis.